<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114217">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01788267</url>
  </required_header>
  <id_info>
    <org_study_id>2011.678</org_study_id>
    <nct_id>NCT01788267</nct_id>
  </id_info>
  <brief_title>Bone Microarchitecture in Young Cystic Fibrosis Patients</brief_title>
  <official_title>Evaluation of the Bone Microarchitecture in a Young Cystic Fibrosis Patients Using High-Resolution Peripheral Quantitative Computed Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with cystic fibrosis are at risk of developing low bone mineral density (BMD)
      potentially leading to pathological fractures at adult age. Recent data from our center and
      others have suggested that low BMD could be observed very early in life. However,
      quantitative bone abnormalities found out by Dual X-ray absorptiometry (DXA) need to be
      confronted to qualitative evaluation of bone microarchitecture (surrogate of bone strength).

      High-Resolution peripheral quantitative computed tomography (HR-pQCT) is a recent technology
      with very high spatial resolution. Images obtained with this technic are considered as
      virtual bone biopsies. It enables an accurate bones' cortical and trabecular surfaces
      exploration in a three-dimensional manner, and therefore provides informations on bone
      microarchitecture as well as bone density.

      The aim of this study is to evaluate bone microarchitecture of paediatric patients matched
      to sex-age-pubertal status-healthy volunteers. In the meantime, biological markers will be
      collected and DXA (Dual-energy x-ray absorptiometry) will be performed in order to explore
      potential correlations HR-pQCT parameters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Total Tibial Bone Mass Density measured by High-Resolution peripheral Quantitative Computed Tomography</measure>
    <time_frame>at the inclusion visit J0</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>total radial bone mass density</measure>
    <time_frame>at the inclusion visit J0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular bone micro-architecture at tibia and radial sites</measure>
    <time_frame>at the inclusion visit J0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers : 1) bone markers : parathyroid hormone (PTH), Calcifediol (25(OH)D3), osteocalcin, Endocrinal markers : IGF-1 (insulin like growth factor ), IGFBP-3, leptin, adiponectin, visfatin, resistin</measure>
    <time_frame>at the inclusion visit J0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers realize a HR-pQCT scanner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cystic Fibrosis patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients realize a HR-pQCT scanner</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>scan examination HR-pQCT</intervention_name>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Cystic Fibrosis patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic Fibrosis patient of both sex

          -  Pubertal patient

          -  Age ≥10 years and ≤18 years on the date of informed consent

          -  FEV1(forced expiratory volume at one second ) ≥ 60% of predicted normal for age,
             gender and height

          -  Patient on a clinical stable period

        Exclusion Criteria:

          -  Unable to maintain  arm and/or leg immobile for 3 minutes

          -  History of solid organ transplantation

          -  Participation in the same time to a clinical trial

          -  Acute pulmonary exacerbation at the time of evaluation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Femme-Mère-Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillipe REIX, MD, PhD</last_name>
      <phone>427 85 50 43</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.reix@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Phillipe REIX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>High-Resolution peripheral Quantitative Computed Tomography</keyword>
  <keyword>Bone Mass Density</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
